
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Drugs In Development, 2022, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.
Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 3, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Drugs In Development, 2022, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.
Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 3, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
63 Pages
- Introduction
- Global Markets Direct Report Coverage
- Gastroenteritis – Overview
- Gastroenteritis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gastroenteritis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastroenteritis – Companies Involved in Therapeutics Development
- Allakos Inc
- Beijing Kangleweishi Biotechnology Co Ltd
- Blue Lake Biotechnology Inc
- Bristol-Myers Squibb Co
- Chongqing Zhifei Biological Products Co Ltd
- Cocrystal Pharma Inc
- Kyowa Kirin Co Ltd
- Lanzhou Institute of Biological Products Co Ltd
- Medicago Inc
- Novo Medi Sciences Pvt Ltd
- RedHill Biopharma Ltd
- Regeneron Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Gastroenteritis – Drug Profiles
- Antibodies for Gastroenteritis – Drug Profile
- benralizumab – Drug Profile
- BLB-300 – Drug Profile
- cendakimab – Drug Profile
- dupilumab – Drug Profile
- HIL-214 – Drug Profile
- lirentelimab – Drug Profile
- norovirus (polyvalent, virus like particle) vaccine – Drug Profile
- norovirus [strains GI.1 + GII.4] (bivalent) vaccine – Drug Profile
- Norovirus Gastroenteritis – Drug Profile
- ondansetron hydrochloride CR – Drug Profile
- rotavirus (virus like particle) vaccine – Drug Profile
- rotavirus vaccine – Drug Profile
- Gastroenteritis – Dormant Projects
- Gastroenteritis – Discontinued Products
- Gastroenteritis – Product Development Milestones
- Featured News & Press Releases
- Mar 30, 2021: Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
- Nov 12, 2019: RedHill Biopharma announces publication of RHB-102 gastroenteritis phase 3 study results in JAMA
- Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
- Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)
- Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
- Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
- Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
- Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
- Apr 19, 2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D
- Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA
- Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
- Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
- Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda
- Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
- Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Gastroenteritis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Universities/Institutes, 2022
- Table 4: Products under Development by Companies, 2022
- Table 5: Products under Development by Universities/Institutes, 2022
- Table 6: Number of Products by Stage and Target, 2022
- Table 7: Number of Products by Stage and Mechanism of Action, 2022
- Table 8: Number of Products by Stage and Route of Administration, 2022
- Table 9: Number of Products by Stage and Molecule Type, 2022
- Table 10: Gastroenteritis – Pipeline by Allakos Inc, 2022
- Table 11: Gastroenteritis – Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022
- Table 12: Gastroenteritis – Pipeline by Blue Lake Biotechnology Inc, 2022
- Table 13: Gastroenteritis – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 14: Gastroenteritis – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
- Table 15: Gastroenteritis – Pipeline by Cocrystal Pharma Inc, 2022
- Table 16: Gastroenteritis – Pipeline by Kyowa Kirin Co Ltd, 2022
- Table 17: Gastroenteritis – Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2022
- Table 18: Gastroenteritis – Pipeline by Medicago Inc, 2022
- Table 19: Gastroenteritis – Pipeline by Novo Medi Sciences Pvt Ltd, 2022
- Table 20: Gastroenteritis – Pipeline by RedHill Biopharma Ltd, 2022
- Table 21: Gastroenteritis – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 22: Gastroenteritis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 23: Gastroenteritis – Dormant Projects, 2022
- Table 24: Gastroenteritis – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Gastroenteritis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Targets, 2022
- Figure 4: Number of Products by Stage and Targets, 2022
- Figure 5: Number of Products by Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.